Thiazolidinedione and Metformin Use and the Risk of Benign Prostate Hyperplasia in Veterans with Diabetes Mellitus
Publication: Journal of Men's Health
Volume 11, Issue Number 4
Abstract
Background: Chronic inflammation is important in the development of benign prostatic hyperplasia (BPH), and certain oral antidiabetic medications have anti-inflammatory properties. The purpose of this study was to determine if use of thiazolidinediones or metformin was associated with a reduced risk of requiring medical or surgical treatment for BPH compared with the use of sulfonylureas among diabetic men.
Methods: We constructed a retrospective cohort of 192,457 male veterans newly prescribed either rosiglitazone, pioglitazone, metformin, or a sulfonylurea. We used Cox proportional hazard regression to assess the association between use of a thiazolidinedione or metformin and the risk of requiring medical or surgical treatment for BPH compared with sulfonylurea use. New BPH treatment was defined by either a new prescription for an α-1 blocker or 5α-reductase inhibitors or a surgical procedure indicated for severe BPH.
Results: In 259,995 person-years of follow-up we identified 14,690 new treatments for BPH. After adjusting for covariates including age, HbA1c, and body mass index, we found no association between rosiglitazone (adjusted hazard ratio [aHR] 1.02; 95% confidence interval [CI] 0.86, 1.20); pioglitazone (aHR 0.79; 95% CI 0.45, 1.38), or metformin use (aHR 0.99; 95% CI 0.94, 1.03) and risk of new medical or surgical treatment for BPH compared with sulfonylureas. Analyses ignoring prescriptions for nonselective α-1 blockers (terazosin, doxazosin, prazosin) from our BPH case definition (n=11,079) yielded similar results.
Conclusions: In this large cohort, we observed no association between the use of thiazolidinediones or metformin and new medical or surgical treatment for BPH compared with sulfonylureas.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. Eur Urol 2003;43:164–175.
2.
Roehrborn CG, Kaplan SA, Noble WD, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: Results from the MTOPS study. J Urol 2005;173:346.
3.
Schenk JM, Kristal AR, Neuhouser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2010;171:571–582.
4.
Rohrmann S, De Marzo AM, Smit E, et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005;62:27–33.
5.
Stamatiou K, Lardas M, Kostakos E, et al. The impact of diabetes type 2 in the pathogenesis of benign prostatic hyperplasia: A review. Adv Urol 2009:818965.
6.
Barni T, Vannelli BG, Sadri R, et al. Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: Gene expression and its cellular localization. J Clin Endocrinol Metab 1994;78:778–783.
7.
Cohen P, Peehl DM, Baker B, et al. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1994;79:1410–1415.
8.
Jiang M, Strand DW, Franco OE, et al. PPARgamma: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation 2011;82:220–236.
9.
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106–1118.
10.
Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355–361.
11.
Jiang M, Fernandez S, Jerome WG, et al. Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell Death Differ 2010;17:469–481.
12.
Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010;70:79–89.
13.
American Diabetes Association. Executive summary: Standards of medical care in diabetes–2012. Diabetes Care 2012;35:S4–S10.
14.
Germeyer A, Jauckus J, Zorn M, et al. Metformin modulates IL-8, IL-1beta, ICAM and IGFBP-1 expression in human endometrial stromal cells. Reprod Biomed Online 2011;22:327–334.
15.
Takemura Y, Osuga Y, Yoshino O, et al. Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab 2007;92:3213–3218.
16.
Penna G, Fibbi B, Amuchastegui S, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 2009;182:4056–4064.
17.
Fibbi B, Penna G, Morelli A, et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010;33:475–488.
18.
Penna G, Mondaini N, Amuchastegui S, et al. Seminal plasma cytokines and chemokines in prostate inflammation: Interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007;51:524–533.
19.
Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9:1092–1099.
20.
Hung AM, Roumie CL, Greevy RA, Liu X, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int 2012;81:698–706.
21.
Roumie CL, Hung AM, Greevy RA, Grijalva CG, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Intern Med 2012;157:601–610.
22.
St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006;164:760–768.
23.
Sutcliffe S, Grubb Iii RL, Platz EA, et al. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int 2012;110:1050–1059.
24.
Araki T, Yokoyama T, Kumon H. Effectiveness of a nonsteroidal anti-inflammatory drug for nocturia on patients with benign prostatic hyperplasia: a prospective non-randomized study of loxoprofen sodium 60 mg once daily before sleeping. Acta Med Okayama 2004;58:45–49.
25.
Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82–86.
26.
Standiford TJ, Keshamouni VG, Reddy RC. Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc Am Thorac Soc 2005;2:226–231.
27.
Vikram A, Jena G, Ramarao P. Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. Br J Pharmacol 2010;161:1708–1721.
28.
Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:1451–1461.
29.
Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol 2008;168:925–931.
30.
Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: Results from a population-based case-control study. Cancer Causes Control 2009;20:1617–1622.
Information & Authors
Information
Published In
Journal of Men's Health
Volume 11 • Issue Number 4 • December 2014
Pages: 157 - 162
PubMed: 25798210
Copyright
Copyright 2014, Mary Ann Liebert, Inc.
History
Published in print: December 2014
Published online: 17 November 2014
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.